Skip to main content

Articles

Page 2 of 64

  1. MicroRNAs (miRNAs) and isomiRs play important roles in tumorigenesis as essential regulators of gene expression. 5’isomiRs exhibit a shifted seed sequence compared to the canonical miRNA, resulting in differen...

    Authors: Xiaoya Li, Birgitta Elisabeth Michels, Oyku Ece Tosun, Janine Jung, Jolane Kappes, Susanne Ibing, Nishanth Belugali Nataraj, Shashwat Sahay, Martin Schneider, Angelika Wörner, Corinna Becki, Naveed Ishaque, Lars Feuerbach, Bernd Heßling, Dominic Helm, Rainer Will…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:190
  2. Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumo...

    Authors: Stephen L. Chan, Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo, Chia-Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean-Frederic Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:189
  3. Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictiv...

    Authors: Diego de Miguel-Perez, Alessandro Russo, Oscar Arrieta, Murat Ak, Feliciano Barron, Muthukumar Gunasekaran, Priyadarshini Mamindla, Luis Lara-Mejia, Christine B. Peterson, Mehmet E. Er, Vishal Peddagangireddy, Francesco Buemi, Brandon Cooper, Paolo Manca, Rena G. Lapidus, Ru-Ching Hsia…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:186
  4. High-grade serous ovarian carcinoma (HGSOC) is clinically dominant and accounts for ~ 80% deaths in all types of ovarian cancer. The delayed diagnosis, rapid development, and wide dissemination of HGSOC collec...

    Authors: Yanhua Du, Xiang Xu, Siang Lv, Han Liu, Hong Sun and Jun Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:185
  5. Cholangiocarcinoma (CCA) is still a deadly tumour. Histological and molecular aspects of thioacetamide (TAA)-induced intrahepatic CCA (iCCA) in rats mimic those of human iCCA. Carcinogenic changes and therapeu...

    Authors: Leticia Colyn, Gloria Alvarez-Sola, M. Ujue Latasa, Iker Uriarte, Jose M. Herranz, Maria Arechederra, George Vlachogiannis, Colin Rae, Antonio Pineda-Lucena, Andrea Casadei-Gardini, Federica Pedica, Luca Aldrighetti, Angeles López-López, Angeles López-Gonzálvez, Coral Barbas, Sergio Ciordia…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:183
  6. Previous in vitro hepatocyte differentiation model showed that TROY was specifically expressed in liver progenitor cells and a small proportion of hepatocellular carcinoma cells, suggesting that TROY may parti...

    Authors: Beilei Liu, Xiaona Fang, Dora Lai-Wan Kwong, Yu Zhang, Krista Verhoeft, Lanqi Gong, Baifeng Zhang, Jie Chen, Qianqian Yu, Jie Luo, Ying Tang, Tuxiong Huang, Fei Ling, Li Fu, Qian Yan and Xin-Yuan Guan
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:182
  7. Authors: Ilaria Martinelli, Chiara Modica, Cristina Chiriaco, Cristina Basilico, James M. Hughes, Simona Corso, Silvia Giordano, Paolo M. Comoglio and Elisa Vigna
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:180

    The original article was published in Journal of Experimental & Clinical Cancer Research 2022 41:112

  8. Prostate cancer (PC) is the most commonly diagnosed male malignancy and an important cause of mortality. Androgen deprivation therapy is the first line treatment but, unfortunately, a large part of patients ev...

    Authors: Lidia Chellini, Marco Pieraccioli, Claudio Sette and Maria Paola Paronetto
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:178
  9. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-019-1098-y.

    Authors: Juntao Sun, Tianyu Zhang, Mengmeng Cheng, Liwen Hong, Chen Zhang, Mengfan Xie, Peijun Sun, Rong Fan, Zhengting Wang, Lei Wang and Jie Zhong
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:177
  10. Authors: Ji Hye Im, Keon Wook Kang, Sun Young Kim, Yoon Gyoon Kim, Yong Jin An, Sunghyouk Park, Byung Hwa Jung, Song-Yi Choi, Jin-Sun Lee and Keon Wook Kang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:176

    The original article was published in Journal of Experimental & Clinical Cancer Research 2018 37:295

  11. The distant metastasis is the primary cause of cancer morbidity and mortality for bladder cancer (BLCA) paitents. All the recommended therapy for it largely depends on how far the cancer has invaded. It has be...

    Authors: Ming Chi, Jiao Liu, Chenxue Mei, Yaxing Shi, Nanqi Liu, Xuefeng Jiang, Chang Liu, Nan Xue, Hong Hong, Jisheng Xie, Xun Sun, Bo Yin, Xin Meng and Biao Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:175
  12. Hypoxia and inflammation tumor microenvironment (TME) play a crucial role in tumor development and progression. Although increased understanding of TME contributed to gastric cancer (GC) progression and progno...

    Authors: Haiyan Piao, Lingfeng Fu, Yuxin Wang, Yang Liu, Yue Wang, Xiangyu Meng, Dong Yang, Xiang Xiao and Jun Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:174
  13. The ETS transcription factor GABPA has long been thought of as an oncogenic factor and recently suggested as a target for cancer therapy due to its critical effect on telomerase activation, but the role of GAB...

    Authors: Zhiqing Fang, Ning Zhang, Xiaotian Yuan, Xiangling Xing, Xiaofeng Li, Xin Qin, Zhengfang Liu, Shiyong Neo, Cheng Liu, Feng Kong, Magnus Björkholm, Yidong Fan and Dawei Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:173
  14. Lung cancer is the leading cause of cancer death, partially owing to its extensive heterogeneity. The analysis of intertumor heterogeneity has been limited by an inability to concurrently obtain tissue from sy...

    Authors: Runzhe Chen, Jun Li, Junya Fujimoto, Lingzhi Hong, Xin Hu, Kelly Quek, Ming Tang, Akash Mitra, Carmen Behrens, Chi-Wan Chow, Peixin Jiang, Latasha D. Little, Curtis Gumbs, Xingzhi Song, Jianhua Zhang, Dongfeng Tan…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:172
  15. RNA-binding proteins (RBPs) and circular RNAs (circRNAs) play important roles in glioblastoma multiforme (GBM). Aerobic glycolysis is a metabolic characteristic of GBM. However, the roles of RBPs and circRNAs ...

    Authors: Jian Song, Jian Zheng, Xiaobai Liu, Weiwei Dong, Chunqing Yang, Di Wang, Xuelei Ruan, Yubo Zhao, Libo Liu, Ping Wang, Mengyang Zhang and Yunhui Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:171
  16. Melanoma is a type of malignant tumor with high aggressiveness and poor prognosis. At present, metastasis of melanoma is still an important cause of death in melanoma patients. However, the potential functions...

    Authors: Qingfeng Shang, Haizhen Du, Xiaowen Wu, Qian Guo, Fenghao Zhang, Ziqi Gong, Tao Jiao, Jun Guo and Yan Kong
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:170
  17. Basal-like breast cancer (BLBC) is the most aggressive subtype of breast cancer because of its aggressive biological characteristics and no effective targeted agents. However, the mechanism underlying its aggr...

    Authors: Zhaorui Miao, Qianhua Cao, Ruocen Liao, Xingyu Chen, Xiaoli Li, Longchang Bai, Chenglong Ma, Xinyue Deng, Zhijun Dai, Jun Li and Chenfang Dong
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:169
  18. Triple negative breast cancer (TNBC) is highly malignant and has a worse prognosis, compared with other subtypes of breast cancer due to the absence of therapeutic targets. KIF23 plays a crucial role in the tu...

    Authors: Zhi Li, Hai-Yan Yang, Xiao-Lan Zhang, Xu Zhang, Yu-Zhou Huang, Xin-Yuan Dai, Liang Shi, Guo-Ren Zhou, Ji-Fu Wei and Qiang Ding
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:168
  19. Interleukin-6 (IL-6) has been reported to be critical in oral squamous cell carcinoma (OSCC). However, the set of pathways that IL-6 might activate in OSCC are not fully understood.

    Authors: Li Xiao, Xue Li, Peilin Cao, Wei Fei, Hao Zhou, Na Tang and Yi Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:166
  20. Circular RNAs (circRNAs) are noncoding RNAs with stable structures with high expression and tissue-specific expression. Studies have shown that circRNA dysregulation is closely related to the progression of tu...

    Authors: Meiqin Yang, Haoran Hu, Sufang Wu, Jianyi Ding, Bo Yin, Baoyou Huang, Fang Li, Xiaoqing Guo and Lingfei Han
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:165
  21. Circular RNAs (circRNAs) function as crucial regulators in multiple cancers, including hepatocellular carcinoma (HCC). However, the roles of circRNAs in HCC remains largely unknown.

    Authors: Yachong Liu, Jia Song, Hongwei Zhang, Zhibin Liao, Furong Liu, Chen Su, Weijian Wang, Mengzhen Han, Lu Zhang, He Zhu, Zhanguo Zhang, Huifang Liang, Lei Zhang, Bixiang Zhang and Xiaoping Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:164
  22. Inevitably developed resistance of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) limited its clinical benefit on non-small cell lung cancer (NSCLC). Upfront comb...

    Authors: Luyao Ao, Shencun Fang, Kexin Zhang, Yang Gao, Jiawen Cui, Wenjing Jia, Yunlong Shan, Jingwei Zhang, Guangji Wang, Jiali Liu and Fang Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:163
  23. The high postoperative recurrence rate and refractoriness of relapsed tumors are still a conundrum for the clinical management of osteosarcoma (OS). New therapeutic options are urgently needed. Depriving the n...

    Authors: Qingxin Fan, Jing Zuo, Hailong Tian, Canhua Huang, Edouard C. Nice, Zheng Shi and Qingquan Kong
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:162
  24. Neuroblastoma is a deadly childhood cancer, and MYCN-amplified neuroblastoma (MNA-NB) patients have the worst prognoses and are therapy-resistant. While retinoic acid (RA) is beneficial for some neuroblastoma pat...

    Authors: Silvia Lampis, Salvatore Raieli, Luca Montemurro, Damiano Bartolucci, Camilla Amadesi, Sonia Bortolotti, Silvia Angelucci, Anna Lisa Scardovi, Giammario Nieddu, Lucia Cerisoli, Francesca Paganelli, Sabrina Valente, Matthias Fischer, Alberto Maria Martelli, Gianandrea Pasquinelli, Andrea Pession…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:160
  25. Cell division cycle 20 homologue (CDC20) is a well-known regulator of cell cycle, as it controls the correct segregation of chromosomes during mitosis. Many studies have focused on the biological role of CDC20...

    Authors: Samantha Bruno, Andrea Ghelli Luserna di Rorà, Roberta Napolitano, Simona Soverini, Giovanni Martinelli and Giorgia Simonetti
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:159
  26. Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers worldwide. Wiskott–Aldrich syndrome protein family member 2 (WASF2) is an integral member of the actin cytoskeleton pathway, which pl...

    Authors: Hye Ri Ahn, Geum Ok Baek, Moon Gyeong Yoon, Ju A Son, Jung Hwan Yoon, Jae Youn Cheong, Hyo Jung Cho, Ho Chul Kang, Jung Woo Eun and Soon Sun Kim
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:158
  27. Epithelial-to-mesenchymal transition (EMT) encompasses a highly dynamic and complex key process which leads to metastatic progression. In high-grade serous ovarian carcinoma (HG-SOC), endothelin-1 (ET-1)/endot...

    Authors: Rosanna Sestito, Piera Tocci, Celia Roman, Valeriana Di Castro and Anna Bagnato
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:157
  28. Circular RNAs (circRNAs) play an important role in the progression of non-small cell lung cancer (NSCLC), especially under tumor hypoxia. However, the precise functions and underlying mechanisms of dysregulate...

    Authors: Dong Wu, Tingting Chen, Xuanna Zhao, Dan Huang, Jiawei Huang, Yujie Huang, Qiu Huang, Zhu Liang, Chunyuan Chen, Min Chen, Dongming Li, Bin Wu and Lixia Li
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:156
  29. The overall response rate to checkpoint blockade remains unsatisfactory, partially due to the immune-suppressive tumor microenvironment. A retinoic acid-related orphan receptor γt (RORγt) agonist (LYC-55716) i...

    Authors: Li Xia, Enming Tian, Mingcheng Yu, Chenglong Liu, Lian Shen, Yafei Huang, Zhongen Wu, Jinlong Tian, Ker Yu, Yonghui Wang, Qiong Xie and Di Zhu
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:155
  30. Osteosarcoma (OS) is a malignant bone tumor mostly occurring in children and adolescents, while chemotherapy resistance often develops and the mechanisms involved remain challenging to be fully investigated.

    Authors: Mingrui Du, Jintao Gu, Chenlin Liu, Nannan Liu, Zhe Yu, Chengpei Zhou, Wei Heng, Zhengcong Cao, Feilong Wei, Kailong Zhu, Yingwen Wang, Wei Zhang, Xiaochang Xue, Yong Zhang and Jixian Qian
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:154
  31. Chemoresistance of pancreatic cancer is the main reason for the poor treatment effect of pancreatic cancer patients. Exploring chemotherapy resistance-related genes has been a difficult and hot topic of oncolo...

    Authors: Zhi-Wen Chen, Jian-Fei Hu, Zu-Wei Wang, Cheng-Yu Liao, Feng-Ping Kang, Cai-Feng Lin, Yi Huang, Long Huang, Yi-Feng Tian and Shi Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:153
  32. Extracellular vesicles (EVs) derived from tumor-associated macrophages are implicated in the progression and metastasis of gastric cancer (GC) via the transfer of molecular cargo RNAs. We aimed to decipher the...

    Authors: Yi Cao, Yi Tu, Jianbo Xiong, Shengxing Tan, Lianghua Luo, Ahao Wu, Xufeng Shu, Zhigang Jie and Zhengrong Li
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:152
  33. Cancer mortality is mainly caused by organ failure and thrombotic events. It has been demonstrated that NETosis, a chromatin release mechanism implemented by neutrophils, may contribute to these lethal systemi...

    Authors: Livia Ronchetti, Irene Terrenato, Margherita Ferretti, Giacomo Corrado, Frauke Goeman, Sara Donzelli, Chiara Mandoj, Roberta Merola, Ashanti Zampa, Mariantonia Carosi, Giovanni Blandino, Laura Conti, Anna Maria Lobascio, Marcello Iacobelli, Enrico Vizza, Giulia Piaggio…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:151
  34. Oral squamous cell carcinoma (OSCC) is one of the common cancers worldwide. The lack of specific biomarkers and therapeutic targets leads to delayed diagnosis and hence the poor prognosis of OSCC patients. Thu...

    Authors: Yan Dong, Liyan Xue, Yan Zhang, Caiyun Liu, Yanguang Zhang, Na Jiang, Xiaoyan Ma, Fangyu Chen, Lingxia Li, Liyuan Yu, Xuefeng Liu, Shujuan Shao, Shufang Guan, Jian Zhang, Qingchun Xiao, Hui Li…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:150
  35. Cyclin-dependent kinase 16 (CDK16) is an atypical PCTAIRE kinase, and its activity is dependent on the Cyclin Y (CCNY) family. Ccnys have been reported to regulate mammary stem cell activity and mammary gland ...

    Authors: Xiao Li, Jinpeng Li, Liming Xu, Wei Wei, Anyi Cheng, Lingxian Zhang, Mengna Zhang, Gaosong Wu and Cheguo Cai
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:149
  36. Despite the promise of dual BRAF/MEK inhibition as a therapy for BRAF-mutant (BRAF-mut) melanoma, heterogeneous responses have been observed in patients, thus predictors of benefit from therapy are needed. We ...

    Authors: Rossella Loria, Valentina Laquintana, Stefano Scalera, Rocco Fraioli, Valentina Caprara, Italia Falcone, Chiara Bazzichetto, Marta Di Martile, Laura Rosanò, Donatella Del Bufalo, Gianluca Bossi, Isabella Sperduti, Irene Terrenato, Paolo Visca, Silvia Soddu, Michele Milella…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:148
  37. Authors: Liling Wen, Huanzi Lu, Qiusheng Li, Qunxing Li, Shuqiong Wen, Dikan Wang, Xi Wang, Juan Fang, Jun Cui, Bin Cheng and Zhi Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:147

    The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:299

  38. Despite recent advances in radiotherapy, radioresistance in patients with pancreatic cancer remains a crucial dilemma for clinical treatment. Cancer stem cells (CSCs) represent a major factor in radioresistanc...

    Authors: Mohammed Salah, Hiroaki Akasaka, Yasuyuki Shimizu, Kenta Morita, Yuya Nishimura, Hikaru Kubota, Hiroki Kawaguchi, Tomomi Sogawa, Naritoshi Mukumoto, Chiaki Ogino and Ryohei Sasaki
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:146
  39. Metastasis is the leading cause of mortality in human cancers, including esophageal squamous cell carcinoma (ESCC). As a pro-inflammatory cytokine, IL-32 was reported to be a poor prognostic factor in many can...

    Authors: Yixuan Sun, Yuzhen Qian, Chunxia Chen, Hongfei Wang, Xiuman Zhou, Wenjie Zhai, Lu Qiu, Xiaowen Zhou, Haoming Ning, Yumiao Zhao, Chao Shi, Lu Han, Yuanming Qi, Yahong Wu and Yanfeng Gao
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:145
  40. Metabolites are intermediate products of cellular metabolism catalysed by various enzymes. Metabolic remodelling, as a biochemical fingerprint of cancer cells, causes abnormal metabolite accumulation. These me...

    Authors: Yidian Fu, Jie Yu, Fang Li and Shengfang Ge
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:144
  41. Cancer cells can evade immune responses by exploiting inhibitory immune checkpoints. Immune checkpoint inhibitor (ICI) therapies based on anti-CTLA-4 and anti-PD-1/PD-L1 antibodies have been extensively explor...

    Authors: Andreia Peixoto, Andreia Miranda, Lúcio Lara Santos and José Alexandre Ferreira
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:143
  42. Challenges exist in the clinical treatment of luminal estrogen receptor α (ERα)-positive breast cancers (BCs) both to prevent resistance to endocrine therapy (ET) and to treat ET-resistant metastatic BCs (MBC)...

    Authors: Sara Pescatori, Stefano Leone, Manuela Cipolletti, Stefania Bartoloni, Alessandra di Masi and Filippo Acconcia
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:141
  43. Selectively utilizing alternative mechanisms to repair damaged DNA in essential factors deficient cancer facilitates tumor genetic evolution and contributes to treatment resistance. Synthetic lethality strateg...

    Authors: Jing Zhang, Mu Chen, Ying Pang, Meng Cheng, Bingsong Huang, Siyi Xu, Min Liu, Hao Lian and Chunlong Zhong
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:140
  44. Glioblastoma multiforme (GBM) is an incurable tumor, with a median survival rate of only 14–15 months. Along with heterogeneity and unregulated growth, a central matter in dealing with GBMs is cell invasivenes...

    Authors: Nadia Trivieri, Alberto Visioli, Gandino Mencarelli, Maria Grazia Cariglia, Laura Marongiu, Riccardo Pracella, Fabrizio Giani, Amata Amy Soriano, Chiara Barile, Laura Cajola, Massimiliano Copetti, Orazio Palumbo, Federico Legnani, Francesco DiMeco, Leonardo Gorgoglione, Angelo L. Vescovi…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:139
  45. Authors: Maria Serena Roca, Tania Moccia, Federica Iannelli, Cristina Testa, Carlo Vitagliano, Michele Minopoli, Rosa Camerlingo, Giulia De Riso, Rossella De Cecio, Francesca Bruzzese, Mariarosaria Conte, Lucia Altucci, Elena Di Gennaro, Antonio Avallone, Alessandra Leone and Alfredo Budillon
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:138

    The original article was published in Journal of Experimental & Clinical Cancer Research 2022 41:83

Annual Journal Metrics